Home » Articles posted by Alan Green

Author Archives: Alan Green

Alan Green talks Advanced Oncotherapy #AVO, Bidstack #BIDS, Brave Bison #BBSN & Xpediator #XPD on Vox Markets podcast

Alan Green discusses Advanced Oncotherapy #AVO, Bidstack #BIDS, Brave Bison #BBSN & Xpediator #XPD with Justin Waite on the Vox Markets podcast. Interview starts at 9 minutes, 35 seconds. Click on the image above to listen.

Tiziana Life Sciences #TILS Announces Proposed U.S. Public Offering of ADSs

New York and London, February 17, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the commencement of an underwritten public offering in the United States of  American Depositary Shares (“ADSs”), representing ordinary shares of nominal value £0.03 each in the capital of the Company (“Ordinary Shares”) on the NASDAQ Global Market.  Each ADS represents five (5) Ordinary Shares.  Tiziana expects to grant the underwriters a 45-day option to purchase additional ADSs offered in the public offering.  There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The price for the Offering has not yet been determined.

All ADSs to be sold in the Offering will be offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering will be within existing shareholder authorities.

Tiziana intends to use the net proceeds from the proposed offering to advance the clinical development of Foralumab, and its other research and development programs, working capital and other general corporate purposes.

ThinkEquity (“ThinkEquity”), a division of Fordham Financial Management, Inc., is acting as the representative of the underwriters in the Offering.

The Offering is being made only by means of a prospectus supplement, which, for the avoidance of doubt, will not constitute a “prospectus” for the purposes of the Prospectus Regulation (as defined below) and has not been reviewed by any competent authority in any Member State (as defined below).

A shelf registration statement on Form F-3 (File No. 333-236013) relating to the ADSs to be issued in the proposed offering was previously filed with the Securities and Exchange Commission (SEC) and was declared effective on February 6, 2020.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email at prospectus@think-equity.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

The person who arranged for the release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.

About Tiziana Life Sciences plc

Tiziana Life Sciences is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. We believe Foralumab is the only fully human anti-CD3 mAb in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as NASH, primary biliary cholangitis (PBS), ulcerative colitis, MS, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

For readers in the European Economic Area

In any member state in the European Economic Area (each, a “Member State”) that has implemented the Prospectus Regulation (as defined below), this announcement is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.

For readers in the United Kingdom

This announcement, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) in connection with the securities which are the subject of the Offering described in this announcement or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) (“Investment professionals”) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) (“High net worth companies, unincorporated associations etc.”) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as “relevant persons”). The ADSs offered in the Offering are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Ordinary Shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

END

For further enquiries:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder 

+44 (0)20 7493 2853

 

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner 

 

+44 (0)20 7213 0883

India’s NMDC plans sharp increase in iron ore output – Argus Media

By Prasenjit Bhattacharya

India’s state-controlled NMDC plans to lift its iron ore output significantly in the 2020-21 fiscal year starting 1 April, anticipating robust sales and higher prices on the back of a supply shortage.

NMDC, India’s largest iron ore producer, is planning an output of 48mn t in 2020-21. The company produced 22mn t in the April-December period of the 2019-20 fiscal year, up by around 0.7pc from 21.85mn t in the same period a year earlier. Total output in 2018-19 was 32.38mn t.

Strategy and detailed plans for increasing output have been worked out and the production target has been proposed to the steel ministry for its approval, said NMDC chairman Baijendra Kumar.

Domestic iron ore prices have increased by 8-30pc in January as mills and pellet producers stock up in anticipation of a squeeze in supplies post-March 2020 when several mining leases of private merchant mining firms will expire. Recent gains in steel prices have also supported iron ore markets.

“NMDC needs to gear up for opportunities coming its way post-March 2020 and should work on an aggressive growth plan to meet the demand of the domestic iron and steel industry,” Kumar said earlier in December.

NMDC’s plan to lift its iron ore output hinges on its ability to restart the 7mn t/yr Donimalai iron ore mine in the southern state of Karnataka, which has not been in operation for more than a year because of a royalty dispute with the Karnataka government.

A court has ruled in favour of NMDC in the dispute, while Delhi has recently made it mandatory for state governments to renew state-run companies’ expiring mining leases by an additional 20 years. “NMDC is very sure of starting operations at Donimalai very soon. Legally and morally NMDC is on the positive side,” said Kumar. But he has not received any communication from the state government yet on the lease renewal.

Securities broking firm IDFC has forecast NMDC’s 2020-21 output at 38.8mn t, expecting Donimalai to be restarted soon.

Link here for full Argus Media article

The supply shortage is also seeing some recommissioning activities among previously mothballed iron ore mines.

In NE Brazil, a jv between AIM listed Cadence Minerals #KDNC and Singapore based commodities group IndoSino Pte Ltd will see the former Anglo American (AAL) and Cliffs Natural Resources owned Amapá iron ore project recommissioned.

With key rail concessions granted to Cadence for shipping in December, this large-scale iron open pit ore mine with associated rail, port and beneficiation facilities is expected to produce 5.3 million tonnes of iron ore by 2024.

CB News – When Advertising Improves the User Experience

FranceTV Publicité has partnered with Mirriad #MIRI, a British Start-Up to offer a product placement offer via augmented reality. Julia Leadbeater, VP Commercial Development for Mirriad in Europe tells us how and why.

What is Mirriad technology?

Julia Leadbeater  : It is a patented artificial intelligence technology which, thanks to an augmented reality process allows producers and distributors to dynamically insert, in post production, brands and / or products in their content ( series, fictions…). This solution improves the viewer’s experience significantly, and represents a tremendous lever for bringing brands to the fore.

Why did you choose France Télévisions?

Julia Leadbeater  : It was a natural choice for us. France Télévisions reaches a wide variety of profiles and receives 12.6 million viewers per day, through its daily soap operas –  Plus Belle La Vie ,  Un si grand soleil  – and its prime time series –  Ten percent ,  Astrid & Raphaëlle  or again  Cain . Current regulations currently limiting product placement to fiction, large broadcasters are essential to create a market with attractive content proposals.
FranceTV Publicité’s offer, effective in encouraging the purchase of products, allows us to carry out post-tests that measure the impact of our devices. The content offers are sold per second of brand exposure over a specific period. We work together to refine the offers according to the needs of advertisers.

What are the first returns?

Julia Leadbeater : Viewers appreciate the fluidity of their advertising experience. According to data from Kantar and Toluna, 95% of respondents appreciate this new advertising format and find that it integrates naturally with content; 92% think that this technique reinforces realism. More concretely, another impact study conducted by Kantar for a T-Mobile campaign in the United States highlighted an increase of 10 points in brand awareness and 12 points on consideration items. In another register, we measured with Spark Neuro the emotional transfer of a content for the benefit of the brands integrated into it. It appears, for example, that the brands of car manufacturers see their appreciation increase when they are inserted in thriller scenes.

EXPERT’S FOCUS

Radovan Aleksic, Commercial Director FranceTV Publicité
Radovan Aleksic, Commercial Director FranceTV Publicité(© Copyright: Virginie Bonnefon)

We are enthusiastic about making our partners benefit from this innovation developed by Mirriad. The quality of the user experience is at the heart of our innovation strategy and we are convinced that augmented reality will revolutionize the product placement market. This new format confirms our conviction: advertising is more effective when it is broadcast at the right time, in the right place and in a quality context.

The France Télévisions group’s offer is one of the most beautiful showcases of fiction in France. In one year, fiction has gathered nearly 800 times more than 3 million viewers on our antennas.

FranceTV Publicité offers its partners three tailor-made product placement offers:
•  Daily , around Un si grand soleil  and  Plus belle la vie ,
•  Prime-time , to be present at the heart of the most powerful fictions in public service:  Candice Renoir ,  Astrid and Raphaëlle ,  Alexandra Ehle …,
•  Events , within the cult series of France 2 as  Dix percent  (season 4).

Link here to read the full article

Alan Green discusses Oil, Corona Virus, Gigafactories, European Metals #EMH & Mirriad #MIRI on the UK Investor Mag Podcast

Alan Green discusses Oil, Corona Virus, Gigafactories, European Metals #EMH & Mirriad #MIRI with Jonathan Roy on the UK Investor Mag Podcast.

Open Orphan #ORPH – Appointment of Group Chief Financial Officer

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe’s only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London, is pleased to announce the appointment of Leo Toole to the role of Group Chief Financial Officer with immediate effect. Leo was previously Interim Chief Financial Officer of Open Orphan plc and Finance Director of the Open Orphan division following the merger with hVIVO.

It is Open Orphan’s intention that Leo be appointed to the Board of Open Orphan as soon as possible, subject to the satisfactory completion of regulatory due diligence checks.

Leo Toole brings over 20 years’ experience in senior finance roles in Pharmaceuticals, Medical Technology and FMCG sectors. He has held senior finance positions at Procter and Gamble, ResMed and Sublimity Therapeutics. Through positions in multinational companies across Europe and in the venture capital space in the UK and Ireland, he has extensive experience in building finance teams, corporate development, equity and debt financing, public markets, and mergers and acquisitions. Leo is a Business graduate of Trinity College Dublin, Ireland and HEC Liège, Belgium. He also holds an MBA with Distinction from INSEAD in France and Singapore.

Commenting on the appointment, Trevor Phillips, CEO of Open Orphan said:

“We are pleased to confirm Leo as the permanent CFO of Open Orphan. Leo brings relevant industry experience and public market experience to the Company and we look forward to him joining the PLC board upon the completion of his regulatory due diligence checks.”

Cathal Friel, Executive Chairman of Open Orphan said:

“I am delighted that we have appointed Leo as CFO. He has worked with Open Orphan for the past year and is therefore well placed to assist with the rapid integration of hVIVO, deliver on our synergies programme and target profitability in the near term. We feel he is an important addition the executive team as we target the rapidly growing CRO pharmaceutical services sector.”

For further information please contact:

Open Orphan plc

Cathal Friel, Executive Chairman

Trevor Phillips, Chief Executive Officer

+353 (0)1 644 0007

+44 (0)20 7347 5350

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Benjamin Cryer

+44 (0)20 7614 5900

Davy (Euronext Growth Adviser and Joint Broker)

Anthony Farrell

+353 (0)1 679 6363

Camarco (Financial PR)

Tom Huddart / Daniel Sherwen

+44 (0)20 3757 4980

Notes to Editors:

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe’s only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London. hVivo supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Corona virus in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 Chronic Constructive Pulmonary Disease viral challenge models. No other company in the world has such a portfolio, with a Belgian company having 1 and one with the west coast of America also having 1 challenge study model. Open Orphan comprises of two commercial specialist CRO services businesses (Venn and hVIVO) and is developing an early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution., The Merger with hVIVO created a European full pharma services company broadening the Company’s customer base and with complementary specialist CRO services, widened the range of the Company’s service offerings.

ECR Minerals #ECR CEO Craig Brown updates on progress at Share Talk

ECR Minerals plc #ECR CEO Craig Brown updates on progress, provides his view on the Australian Gold exploration sector and discusses the recent sale of the SLM gold project at Share Talk. Link here

Vox Markets Q&A with Open Orphan #ORPH Exec Chairman Cathal Friel

Open Orphan #ORPH Exec Chairman Cathal Friel discusses the completion of the hVIVO acquisition and provides an update on activities with Abraham Darwyne at Vox Markets.

Cadence Minerals #KDNC – Macarthur Minerals (TSX-V: MMS) announces encouraging initial drill results at the Pilbara Hillside Project.

Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) is pleased to note today’s update from Macarthur Minerals (TSX-V: MMS) (“Macarthur”), that it’s Joint Venture Partner, Fe Limited (“FEL”) has received encouraging results from its first phase preliminary drilling at the Hillside Project in Western Australia targeting underground extensions to the periodically outcropping mineralised gossan identified during previous reconnaissance.  A total strike length of 14km was mapped and sampled at outcrop resulting in high grade rock chip results as reported in ASX announcement October 9, 2019.

Cadence Minerals Holding in Macarthur

Cadence holds approximately 6% of the issued equity interest in Macarthur, which is an Australian mining exploration company focused primarily on iron ore, nickel, lithium and gold in Western Australia. It also has a lithium project in Nevada, USA.

Highlights:

  • Encouraging results received from recent Hillside drilling.
  • Results demonstrate support for mineralised gossan model.
  • Down dip extension of mineralised gossan intercepted in two holes.
  • Anomalous results received include:
  • HRC 001: 1m @ 0.19% Cu, 230ppm Co, 0.14% Zn, 0.07ppm Au from 28m.
  • HRC 022: 1m @ 0.74% Cu, 349ppm Co, 0.41% Zn, 0.14ppm Au from 83m.
  • HRC 036: 1m @ 0.18% Cu, 0.12% Zn from 25m, 1m @ 0.27% Cu from 40m.
  • All Intercepts demonstrate down dip extensions to the mineralised gossan at surface.

A total of 1798m from 36 holes were drilled at approximately 1km intervals targeting underground extensions to the periodically outcropping mineralised gossan identified during previous reconnaissance.

Limited historical targeting data was available, and first pass hole locations were chosen using estimated dip and dip direction from the interpreted lineament of the mineralised strike. Supporting information included field observations, a coincident westerly dipping magnetic anomaly with its eastern extent coinciding roughly with the interpreted gossan lineament and the presence of highly leached surface lithologies indicating the possibility of sulphides at depth.

FEL and Macarthur have now received all results of the assays and initial interpretation shows three holes have been positively identified to have intercepted down dip extensions of the surface gossan. These holes span the entire length of the mapped strike length demonstrating down dip extension of the surface mineralisation.

The full release can be found at: https://web.tmxmoney.com/article.php?newsid=6135740381549710&qm_symbol=MMS

This news release is not for distribution to United States Services or for Dissemination in the United States.

– Ends –

For further information:

Cadence Minerals plc                                                    +44 (0) 207 440 0647
Andrew Suckling
Kiran Morzaria
WH Ireland Limited (NOMAD & Broker)                                 +44 (0) 207 220 1666
James Joyce
James Sinclair-Ford
Novum Securities Limited (Joint Broker)                                 +44 (0) 207 399 9400
Jon Belliss

 

 

Qualified Person

Kiran Morzaria B.Eng. (ACSM), MBA, has reviewed and approved the information contained in this announcement. Kiran holds a Bachelor of Engineering (Industrial Geology) from the Camborne School of Mines and an MBA (Finance) from CASS Business School.

Forward-Looking Statements:

Certain statements in this announcement are or may be deemed to be forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ”believe” ”could” “should” ”envisage” ”estimate” ”intend” ”may” ”plan” ”will” or the negative of those variations or comparable expressions including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth results of operations performance future capital and other expenditures (including the amount. nature and sources of funding thereof) competitive advantages business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.  Many factors could cause actual results to differ materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions competition environmental and other regulatory changes actions by governmental authorities the availability of capital markets reliance on key personnel uninsured and underinsured losses and other factors many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions. The Company cannot assure investors that actual results will be consistent with such forward-looking statements.

 

Open Orphan #ORPH – Value the Markets Webinar

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be hosting a webinar for investors at 7pm on Tuesday 11th February. For those wishing to join the event the participant details are below.

Join via Website: https://vtm.clickmeeting.com/orph

Join via Phone: +44 (20) 7048-4146

When prompted please provide the Participant’s PIN code 159543# followed by the # key

For further information please contact

Open Orphan plc

Cathal Friel, Executive Chairman              

Trevor Phillips, Chief Executive Officer

 

+353 (0)1 644 0007

+44 (0)20 7347 5350

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Benjamin Cryer

+44 (0)20 7614 5900

Davy (Euronext Growth Adviser and Joint Broker)

Anthony Farrell

+353 (0)1 679 6363

Camarco (Financial PR)

Tom Huddart / Daniel Sherwen

+44 (0)20 3757 4980

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Notes to Editors:

Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools.  In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The Merger with hVIVO created a European full pharma services company broadening the Company’s customer base and with complementary specialist CRO services, widened the range of the Company’s service offerings.

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.